enGene Therapeutics Inc. (ENGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.51M
Last updated: Nov 17, 2026 at 4:33 PM ET
enGene Therapeutics Inc. (ENGN) Statistics
enGene Therapeutics (ENGN) has a market cap of $161.51M and an enterprise value of $145.84M. Its share count is up 36.47% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 9.70% below the market cap, as cash exceeds debt.
| Market Cap | $161.51M |
|---|---|
| Enterprise Value | $145.84M |
| Latest price (Nov 17, 2026) | $1.72 |
Key Dates
The next earnings report is expected on Dec 22, 2026, covering the quarter ending Oct 31, 2026.
| Next Earnings Date | Dec 22, 2026 (expected) |
|---|---|
| Last Earnings Date | Sep 8, 2026 |
| Fiscal Year End | October |
Valuation Ratios
| Forward P/S | 34.5x |
|---|---|
| P/B Ratio | 0.5x |
Price Statistics
The stock is down 79.84% over 52 weeks and trades 3.91% below its 50-day average.
| Beta (1Y) | 2.13 |
|---|---|
| 52-Week Change | -79.84% |
| 1-Month Change | +8.86% |
| 3-Month Change | -7.03% |
| 6-Month Change | +12.42% |
| Total Return (1Y) | -79.84% |
| Total Return (3Y CAGR) | -39.19% |
| Return vs SPY (1Y) | -86.56% |
| Max Drawdown (1Y) | -88.17% |
| Max Drawdown (3Y) | -92.11% |
| Sharpe Ratio (1Y) | -0.77 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $1.79 |
| 200-Day Average | $3.87 |
| 52-Week Range | $1.40 to $12.25 |
| RSI (14 Days) | 48.1 |
| Average Volume (20 Days) | 1.75M |
Financial Position
Current assets cover 10.21x current liabilities, and total debt is 0.11x shareholder equity.
| Current Ratio | 10.21x |
|---|---|
| Quick Ratio | 10.21x |
| Debt / Equity | 0.11x |
| Interest Coverage | -38.34x |
Returns and Efficiency
Return on invested capital is -42.15% and return on equity is -56.61% over the last 12 months.
| Return on Equity (ROE) | -56.61% |
|---|---|
| Return on Assets (ROA) | -45.21% |
| Return on Invested Capital (ROIC) | -42.15% |
| ROE (5Y Average) | -53.12% |
| ROA (5Y Average) | -44.39% |
Scores
ENGN has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$171.00K |
| Operating Income | -$136.65M |
| Pretax Income | -$130.86M |
| Net Income | -$130.36M |
| Reported EPS (TTM) | -$1.13 |
Trailing 12 months through Jul 31, 2026.
Balance Sheet
Shareholder equity funds 79.87% of the $288.32M in total assets.
| Cash and Equivalents | $41.02M |
|---|---|
| Total Debt | $25.35M |
| Net Cash | $15.67M |
| Net Cash Per Share | $0.22 |
| Working Capital | $250.69M |
| Shareholder Equity | $230.29M |
| Book Value Per Share | $3.30 |
| Total Assets | $288.32M |
| Total Liabilities | $58.03M |
Balance sheet as of Jul 31, 2026.
Cash Flow
| Operating Cash Flow | -$103.31M |
|---|---|
| FCF Per Share | -$1.55 |
| Depreciation and Amortization | $2.08M |
Trailing 12 months through Jul 31, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +18.81% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +18.81% |
Dividends and Yields
ENGN does not pay a dividend.
| Buyback Yield | -11.51% |
|---|---|
| Shareholder Yield | -11.51% |
Peer Position
Against 4 similar companies, ENGN has the 3rd highest ROIC.
ROICPeer median -68.60%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -64.32%
| ROIC | -42.15% vs -68.60% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -64.32% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ENGN
What is ENGN's market cap?
enGene Therapeutics has a market cap of $161.51M. Its enterprise value, which adds debt and subtracts cash, is $145.84M.
How many shares of ENGN are outstanding?
enGene Therapeutics has 69.73M shares outstanding. The count is up 36.47% from a year earlier.
Does ENGN pay a dividend?
No. enGene Therapeutics does not pay a dividend.
How much debt does ENGN have?
enGene Therapeutics has $25.35M of total debt and $41.02M of cash and equivalents, a net cash position of $15.67M.
ENGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors